NBP14 Targets Possible Primary Driver of Neurodegeneration Neuro-Bio Ltd, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, finds its new drug candidate
Oxford, UK, 6th April 2022 / Sciad Newswire / Neuro-Bio Ltd, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, finds its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimer’s disease.Publishing their work in Alzheimer’s & D.
Novel Drug From Neuro-Bio Effective in a Mouse Model of Alzheimer’s Disease - read this article along with other careers information, tips and advice on BioSpace